Interestingly, the sixth CAR-T product, recently approved by the US FDA for medical use in patients with R/R multiple myeloma (MM), utilizes two VHHs targeting two different B-cell maturation antigen (BCMA) epitopes [59] (Fig. 1). Here, TNFRSF17 is linked to plasma cell myeloma.